ResearchPod Summary
This guideline provides a comprehensive framework for managing female fertility preservation (FP) in patients facing potential reproductive loss. As medical treatments for cancer, autoimmune diseases, and gender-affirming care can be gonadotoxic, preserving fertility is a critical component of survivorship and quality of life. The guideline specifically addresses four populations: post-pubertal women with cancer, those with benign diseases (e.g., endometriosis, Turner syndrome), transgender men, and women requesting elective oocyte cryopreservation due to age-related fertility decline.
The guideline emphasizes that FP should be integrated into multidisciplinary care. Successful programs require a clear team structure, standardized referral pathways, and immediate access to counseling regarding the financial and legal implications of storing reproductive material. A key emphasis is placed on psychological support, recommending that patients at risk of distress be identified and referred to counseling throughout their decision-making process.
For most clinical indications, oocyte and embryo cryopreservation are considered established, first-line methods. The guideline recommends the GnRH antagonist protocol for ovarian stimulation because of its safety and efficiency in urgent clinical timelines. Ovarian tissue cryopreservation (OTC) is identified as a valuable strategy when time is limited or if stimulation is not feasible, although it is considered more innovative and less standardized than oocyte freezing. Medical methods, such as the use of GnRH agonists during chemotherapy, are supported for specific patient groups (e.g., breast cancer) but should not be viewed as a substitute for established cryopreservation techniques. The guideline also stresses that elective procedures for age-related fertility loss require detailed, case-by-case counseling due to the significant cost, ethical considerations, and variable success rates.
Transitioning from FP to future pregnancy involves careful assessment. The guidelines highlight that patients must be evaluated for long-term health effects of their primary disease treatment—such as cardiovascular or uterine function—before attempting pregnancy. Obstetric care for these patients should be considered high-risk, requiring closer monitoring to manage risks like preterm birth or growth restriction.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.